2 years ago

Mironid Raises £35M in Series A Extension for Hereditary Kidney Disease Therapeutics

  • Mironid, a Glasgow-based biopharmaceutical company developing small molecule therapeutics for the treatment of life-threatening hereditary kidney disease, has extended its Series A funding to £35 million

  • The round was led by Roche Venture Fund with participation from existing investors Epidarex Capital, Sofinnova Partners, BioGeneration Ventures, the University of Strathclyde, Scottish Enterprise and the European Investment Fund

  • The company plans to use the funds to progress its lead discovery programme through IND-enabling studies and to extend its patent estate.

      • ProblemHealthcare

      "Mironid is addressing the lack of effective treatments for Autosomal Dominant Polycystic Kidney Disease (ADPKD), a common hereditary kidney disorder that leads to the growth of fluid-filled cysts and has limited treatment options."

      Solution

      "Mironid is developing small molecule therapeutics, specifically LoAc® drug candidates, that directly target the abnormally high kidney cAMP levels which drive cyst formation, aiming to provide a treatment for ADPKD."

      Covered on